Clinical Trials Logo

Clinical Trial Summary

Schizophrenia (SZ) is a highly debilitating neuropsychiatric disorder of young adulthood onset and a leading cause of disability worldwide. While treatments delivered at early stages of the disorder may be effective at reducing psychosis or altering the course of the disease, there are currently no biomarkers capable of identifying subjects in early stages of SZ who are likely to respond to treatment and would be good candidates for available proactive, symptomatic or future disease-modifying treatments; or those who would not respond and can be spared unnecessary medication exposure. The lack of these vitally important biomarkers provides a compelling rationale for the present multidisciplinary research project, which aims to develop and validate highly promising noninvasive and objective proton magnetic resonance spectroscopy (1H MRS)-based biomarkers for monitoring treatment response in early stages of SZ. In support of the viability of this overall objective is a large body of data, reported by the applicants and others, that show (a) that levels of glutamate (Glu) and - aminobutyric acid (GABA) - respectively, the major excitatory and inhibitory amino acid neurotransmitter systems - are abnormally elevated in medication-naïve and unmedicated first episode and chronic SZ patients; (b) that the effect of treatment with antipsychotic medications in these populations may be to lower or normalize brain levels of both Glu and GABA. To investigate the potential of these in vivo brain Glu and GABA abnormalities to serve as biomarkers of treatment response in early-stage SZ, the applicants propose to use 1H MRS to measure Glu and GABA levels in the largest cohort of medication-free SZ subjects to date, at baseline and following 4 weeks of antipsychotic treatment.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03323437
Study type Interventional
Source Weill Medical College of Cornell University
Contact
Status Completed
Phase Phase 4
Start date September 15, 2017
Completion date May 31, 2023

See also
  Status Clinical Trial Phase
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Recruiting NCT04298450 - ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention N/A
Enrolling by invitation NCT03090490 - 10-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals N/A
Recruiting NCT06423651 - Benefits of Combining MCT With CR in the Recovery of Patients With Psychotic Spectrum Disorders N/A
Completed NCT06040944 - Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients
Recruiting NCT04452175 - Cigarette Consumption After switchinG to High or Low Nicotine strENght E-cigaretteS In Smokers With Schizophrenia N/A
Completed NCT03501888 - Cognitive Behavior Therapy for Patients With Psychoses. N/A
Completed NCT05601063 - Ascertaining Diagnosis Classification With Elicited Speech
Recruiting NCT05877716 - EPI-MINN: Targeting Cognition and Motivation - National N/A
Completed NCT03955549 - Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial Phase 3
Completed NCT03235908 - Copeptin in Outcome Prediction of an Acute Psychotic Episode
Recruiting NCT05622201 - A Randomized Controlled Trial With Rituximab for Psychotic Disorder in Adults Phase 2
Recruiting NCT05491486 - Mindfulness, Empathy and the Oxytocinergic System in Persons With Schizophrenia N/A
Completed NCT04916496 - Acceptance and Commitment Therapy-based Lifestyle Counselling Programme for Early Psychosis on Physical Activity N/A
Recruiting NCT04104347 - Metacognitive Training and Insight in Schizophrenia N/A
Recruiting NCT05664594 - State Representation in Early Psychosis - Project 4 N/A
Recruiting NCT05538832 - Remote State Representation in Early Psychosis Early Phase 1
Completed NCT02220504 - 3-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals N/A
Completed NCT04665401 - Personalizing Interventions Using Real-World Interactions N/A
Recruiting NCT03919760 - Early Psychosis Intervention - Spreading Evidence-based Treatment